Experience

Aerami Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Board Director -- Lead Director and Audit Committee (Chairman); Compensation Committee

  • Jun 2013 - Present

  Served as Board Member 2013 to 2018, and CFO from 2017 to 2019 raising $45M. Currently Board Observer and Advisor Served as Board Member 2013 to 2018, and CFO from 2017 to 2019 raising $45M. Currently Board Observer and Advisor



Amarantus BioScience

• United States
• Biotechnology Research
• 1 - 100 Employee

• Board Director -- Audit Committee (Chairman); Compensation Committee

  • Jul 2014 - Present

  Restructuring underway. Restructuring underway.



SteadyMed Therapeutics

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Board Director -- Audit Committee (Chairman); Compensation Committee

  • Mar 2015 - Aug 2018

  SteadyMed (NASDAQ: STDY) was acquired by United Therapeutics in August 2018 Joined at IPO, established audit committee. SteadyMed (NASDAQ: STDY) was acquired by United Therapeutics in August 2018 Joined at IPO, established audit committee.



WaferGen Biosystems

• United States
• Biotechnology Research
• 1 - 100 Employee

• CFO / Co-President

  • Sep 2010 - Mar 2012

  Wafergen (OTC: WGBS) was acquired by Takara Bio Inc. - Hired to raise capital and work with the CEO, COO and Board of Directors to move the company into full commercialization, starting with aggressive sales effort. - Raised $31 million private placement with top tier life science investors after closing $7 million in a previous round. - Served as Co-President (with COO) in the absence of a CEO. Established relationships with upper-tier bankers and analysts. Presented at investor conferences.



Asante Solutions

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• CFO

  • Oct 2008 - Sep 2010

  Asante was acquired by Bigfoot Biomedical, Inc. - Joined to partner with the CEO and move the company through 510(k) clearance into full commercialization. Developed model for scale-up. - Selected bankers; prepared for $50 million mezzanine financing after raising $18 million Series B round. Mezzanine postponed due to FDA issues. Asante was acquired by Bigfoot Biomedical, Inc. - Joined to partner with the CEO and move the company through 510(k) clearance into full commercialization. Developed model for scale-up. - Selected bankers; prepared for $50 million mezzanine financing after raising $18 million Series B round. Mezzanine postponed due to FDA issues.



Guava Technologies

• CFO

  • Jul 2006 - Sep 2008

  Guava Technologies was acquired by Millipore, then Merck - Hired to partner with the CEO and lead the company to higher levels of performance in all areas. - Accomplished key objectives and positioned the company for a liquidity event. Grew revenues from $9 to ~$25 million range. - Worked with CEO and board in M&A activities – engaged a top-tier banker and ran a formal “process” to sell the company. - Assisted in completing an important partnership with Millipore Corp, and partial acquisition.



Sanderling Ventures

• United States
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• CFO & Principal

  • Sep 2004 - Jul 2006

  - Assisted in raising a $420 million fund. - Participated in all investment decisions. Worked with ad hoc teams to close deals – financings, mergers and acquisitions of portfolio companies. - Served as CFO for twelve early stage portfolio companies -- e.g., in the absence of a full time CEO, oversaw the design and construction of a state-of-the-art biotech facility. - Assisted in raising a $420 million fund. - Participated in all investment decisions. Worked with ad hoc teams to close deals – financings, mergers and acquisitions of portfolio companies. - Served as CFO for twelve early stage portfolio companies -- e.g., in the absence of a full time CEO, oversaw the design and construction of a state-of-the-art biotech facility.